Integrative analysis of plasma small-molecule and gut-microbiome markers of sarcopenia in a pilot study within an Indian cohort

在一项针对印度人群的试点研究中,对血浆小分子和肠道微生物组标志物进行肌少症的综合分析

阅读:1

Abstract

Sarcopenia, the age-associated decline in muscle mass and strength, is influenced by metabolic, inflammatory, and microbiome-related factors. However, integrative analyses combining these dimensions remain limited. This study applies a multi-omics workflow to identify plasma metabolite, lipid, and microbiome signatures linked to sarcopenia in older adults. Forty community-dwelling adults aged 60–87 years were classified as sarcopenic (n = 15) or non-sarcopenic (n = 25) using EWGSOP2 criteria, incorporating dominant hand grip strength (DHGS), chair rise time, psoas muscle cross-sectional area (CT), and SARC-F score. Plasma metabolomics (308 metabolites) and lipidomics (295 lipids) were performed using LC-MS/MS. A support vector machine (SVM) model with recursive feature elimination identified discriminative metabolites. Gut microbiome profiles were generated using 16 S rRNA sequencing and correlated with metabolite patterns. DHGS was the strongest clinical predictor of sarcopenia (AUROC = 0.93). Sarcopenic subjects exhibited higher systemic inflammation (neutrophil-to-lymphocyte ratio, p = 0.011) and elevated plasma arachidonic acid (p = 0.013). Thirteen lipid species—primarily lysophosphatidylcholines, lysophosphatidylethanolamines, hexosylceramides, and acylcarnitines—were significantly associated with sarcopenia. Twenty-four metabolites, including spermidine, lysine, homoarginine, and karanjin, were correlated with sarcopenia. A 16-metabolite panel derived from SVM modeling classified sarcopenic status with 89% accuracy. Microbiome analysis identified 54 taxa linked to sarcopenia, including a subgroup with a dysbiotic, pro-inflammatory microbiome. This integrative multi-omics study identifies exploratory candidate markers—13 lipids, 16 metabolites, and 54 microbial taxa—associated with sarcopenia, highlighting host–microbiome metabolic interactions and providing a framework for early biomarker discovery. Using this pilot study a validation in a larger independent cohort can be designed. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1038/s41598-026-35476-8.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。